RhIL-11 Injection(Oprelvekin), CAS No.: 145941-26-0, (Recombinant Human Interleukin-11) – A Drug To Increase Platelet Count, RhIL-11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial

Introduction:

RhIL-11 Injection (Oprelvekin) is a synthetic protein that is used to stimulate the growth of platelets in the body. It is a drug that is used to treat low platelet count in patients who are undergoing chemotherapy. The drug is also known as Recombinant Human Interleukin-11.

RhIL-11 Injection is a recent development in the medical industry and has been found to be effective in the treatment of low platelet count. The drug acts by stimulating the production of platelets in the bone marrow, which is essential for the clotting process of the blood.

Product Description:

RhIL-11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial is a white to off-white lyophilized powder that is available in three different quantities. The powder is sterile and is intended for intravenous injection. The product is packed in glass vials and is sealed with a rubber stopper.

RhIL-11 Injection is available in the following strengths:

- 0.75mg/vial

- 1.5mg/vial

- 3mg/vial

Each vial contains a single dose of the drug and must be reconstituted before injection. The product is manufactured in compliance with Good Manufacturing Practices (GMP) guidelines and is of high quality.

Product Features:

1. Highly Effective:

RhIL-11 Injection is a highly effective drug in stimulating the production of platelets. The drug has been found to be effective in treating low platelet count in patients undergoing chemotherapy.

2. Long Shelf Life:

The product has a long shelf life of up to two years, which makes it a cost-effective option for merchants.

3. Easy to Use:

RhIL-11 Injection is easy to use as it comes in a lyophilized form that must be reconstituted before use. The product is intended for intravenous injection, which makes it easy for medical professionals to administer.

4. Available in Different Quantities:

RhIL-11 Injection is available in three different quantities, which makes it suitable for different patient needs.

5. Manufactured in Compliance with GMP Guidelines:

The product is manufactured in compliance with Good Manufacturing Practices (GMP) guidelines, which ensures that the product is of high quality.

Product Benefits:

1. Increases Platelet Count:

RhIL-11 Injection is a drug that is used to increase the platelet count in patients who are undergoing chemotherapy. The drug has been found to be effective in increasing the platelet count, which reduces the risk of bleeding.

2. Prevents Bleeding:

RhIL-11 Injection prevents bleeding by increasing the production of platelets in the bone marrow. The increased platelet count ensures that the blood is able to clot effectively.

3. Reduces Risk of Infection:

RhIL-11 Injection reduces the risk of infection by increasing the production of white blood cells. The increased production of white blood cells helps to fight against infections that may occur during chemotherapy treatment.

4. Improves Quality of Life:

RhIL-11 Injection improves the quality of life of patients who are undergoing chemotherapy. The drug reduces the risk of bleeding and infection, which can cause discomfort and pain.

Conclusion:

RhIL-11 Injection is a highly effective drug that is used to increase the platelet count in patients undergoing chemotherapy. The drug is available in three different quantities and is easy to administer. The product has a long shelf life and is manufactured in compliance with GMP guidelines. RhIL-11 Injection is an excellent product for merchants who are looking to supply quality medical products to their customers.

Active ingredient: Recombinant Human Interleukin-11,0.75mg,1.5mg & 3mg

with inactive ingredients  of Glycine 23 mg, Na2HPO4 0.85 mg, NaH2 PO4 0.48mg per vial.

Pharmacology:

Recombinant Human Interleukin-11, produced by recombinant DNA technology, is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production, so as to elevate platelet count without significant change of platelet function.

Pre-clinical studies have shown that mature megakaryocytes which develop during in vivo treatment with rhIL-11 are ultra-structurally and functionally normal and possessed a normal life span.

Toxicology:

Safety Pharmacology:

IL-11 has shown to have non-hematopoietic activities in animals including the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesis and neurogenesis.

Toxicity of Repetitive Administration:

Continuous dosage (2 to 13 weeks) in nonhuman primates produced joint capsule and tendon fibrosis and periosteal hyperostosis. The relevance of these findings to human is unclear.

Genetic Toxicity:

In vitro studies have shown that rhIL-11 is not mutagenic.

Reproduction Toxicity:

Although prolonged estrus cycles have been noted at 2 to 20 times the human dose, no effects on fertility have been observed in rats treated with rhIL-11 at doses up to 1000µg/kg/day.

The studies on fertility and early embryonic development of rats and organogenesis of rats and rabbits have shown that parental toxicity was observed when rhIL-11 was given at dose of 2~20 times the human dose (>100µg/kg/day) in the rat and at 0.02~2.0 times of human dosage (>1µg/kg/day) in the rabbit. Findings in pregnant rats consisted of transient hypoactivity and dyspnea after administration (maternal toxicity), as well as prolonged estrus cycle, increased early embryonic deaths and decreased numbers of live fetuses. In addition, low fetal body weights and a reduced number of ossified sacral and caudal vertebrae (i.e. retarded fetal development) occurred in rats at 20 times the human dose without long-term abnormality of behavior or development. Findings in pregnant rabbits consisted of decreased fecal/urine eliminations as well as decreased food consumption, body weight loss, abortion, increased embryonic and fetal deaths, and decreased numbers of live fetuses, without observation of teratogenic effects. There are no adequate and well-controlled studies of rhIL-11 in pregnant women. rhIL-11 should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known if rhIL-11 is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from rhIL-11, a decision should be made whether to discontinue nursing or to discontinue rhIL-11, taking into account the importance of the drug to the mother.

[Name]

Generic Name: Oprelvekin

Trade Name: JIJUFEN

Chemical Name: Human Interleukin-11 for Injection

The only drug approved by FDA for prevention and treatment of Chemoradiotherapy-induced thrombocytopenia.

Dosage: Injection

Specification: 0.75mg（600MU）/vial，1.5mg（1200MU）/vial，3mg（2400MU）/vial

The only preparation of interleukin-11 expressed by eukaryotic cells

[Indication]

Prevention and treatment of Chemoradiotherapy-induced thrombocytopenia.

Entrepreneurship Imprint

1993

On December 31, Hangzhou Jiuyuan Gene Engineering Co., Ltd. was registered and established in Hangzhou High-tech Development Zone.

Year 2013

In October, the company reformed its marketing system and established a development strategy of "market first, overall marketing".

2018

The company embarked on a major transformation, taking the road of placing equal emphasis on innovative drugs and generic drugs.

2020 year

The company's R&D center settled in Hangzhou Pharmaceutical Town as a whole.

The company's sales exceeded 1 billion yuan.

Company Honor

Zhejiang province per mu benefit leading enterprises

Gene-engineering New Drug R&D Technology and Service Sub-platform

Provincial Post-doctoral Scientific Research Working Center

Excellent industrial products in Zhejiang Province

Hangzhou Academician Expert Working Center

Hangzhou Top Ten New High-tech Enterprise

Zhejiang Green Enterprise

FAQ

Q: Are you trading company or manufacturer?

A: We are professional manufacturer specialized in the research, development, manufacture and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993.

And we trade our products with our clients directly.

Q: How many different types of products your company manufactures?

A: Now we have 36 products including pipeline products. All the pharmaceutical manufacturing activities are carried as per GMP requirements. The day to day licensing and regulatory activities are controlled by SFDA.

Why choose us?

• Our company is a leading supplier and manufacturer of Oncology Injection products with competitive pricing.
• Service commitment is an effective marketing tool to help our company seize market opportunities and establish competitive advantages.
• With years of experience, our Chinese factory has established a reputation for providing the best quality Oncology Injection products in the market.
• Our company always adheres to the development concept of focusing on market development and quality as the foundation and the business principle of integrity-based.
• Our Chinese factory utilizes innovative production techniques to create Oncology Injection products that meet the industry's highest standards.
• Our company has been adhering to the customer-oriented, technology first principle, to provide customers with reasonable products, quality service.
• Our years of experience in the Oncology Injection industry have allowed us to develop a deep understanding of our clients' needs and preferences.
• Looking back on the past and looking forward to the future, our RhIL-11 Injection(Oprelvekin), CAS No.: 145941-26-0, (Recombinant Human Interleukin-11) – A Drug To Increase Platelet Count, RhIL-11 Injection Lyophilized Powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial will be market-oriented, survive with quality and develop with reputation.
• Our Chinese factory is equipped with modern facilities and equipment that enable us to produce high-quality Oncology Injection products efficiently.
• Our company directly faces the end customers and truly realizes the win-win situation between the company and the customers.

Hot Tags: rhil-11 injection(oprelvekin), cas no.: 145941-26-0, (recombinant human interleukin-11) – a drug to increase platelet count, rhil-11 injection lyophilized powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial, China rhil-11 injection(oprelvekin), cas no.: 145941-26-0, (recombinant human interleukin-11) – a drug to increase platelet count, rhil-11 injection lyophilized powder (vial): 0.75mg/vial, 1.5mg/vial, 3mg/vial manufacturers, suppliers, factory, oncology manufacturing injection, anti tumor injection, tumor packaging injection, PegFilgrastim injection, malignant tumor medication injection, tumor injection